Literature DB >> 21268618

Synthesis of the antiproliferative agent hippuristanol and its analogues via Suárez cyclizations and Hg(II)-catalyzed spiroketalizations.

Kontham Ravindar1, Maddi Sridhar Reddy, Lisa Lindqvist, Jerry Pelletier, Pierre Deslongchamps.   

Abstract

A full account of the synthesis of hippuristanol and its analogues is described. Hecogenin acetate was identified as a suitable and economical starting material for this work, and substrate-controlled stereoselection was obtained throughout the construction of the key spiroketal unit. Suárez cyclization was first used, but Hg(II)-catalyzed spiroketalization of the 3-alkyne-1,7-diol motif was finally identified as the most convenient strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21268618     DOI: 10.1021/jo102054r

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  5 in total

1.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

Review 2.  Therapeutic Opportunities in Eukaryotic Translation.

Authors:  Jennifer Chu; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 3.  Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A.

Authors:  Regina Cencic; Jerry Pelletier
Journal:  Translation (Austin)       Date:  2016-01-04

4.  Tandem aldehyde-alkyne-amine coupling/cycloisomerization: A new synthesis of coumarins.

Authors:  Maddi Sridhar Reddy; Nuligonda Thirupathi; Madala Haribabu
Journal:  Beilstein J Org Chem       Date:  2013-01-28       Impact factor: 2.883

5.  Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A.

Authors:  R Cencic; F Robert; G Galicia-Vázquez; A Malina; K Ravindar; R Somaiah; P Pierre; J Tanaka; P Deslongchamps; J Pelletier
Journal:  Blood Cancer J       Date:  2013-07-19       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.